Tenpoint Therapeutics Ltd. to Participate at Citi Biotech Private Access Day
LONDON & SEATTLE--(BUSINESS WIRE)-- Tenpoint Therapeutics, Ltd. ('Tenpoint'), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics, will participate in one-on-one meetings at the virtual Citi Biotech Private Access Day on April 24.
Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics, will participate in one-on-one meetings at the virtual Citi Biotech Private Access Day on April 24.
Share
About Tenpoint Therapeutics
Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts, and geographic atrophy. Its lead asset, BRIMOCHOL™ PF, is a novel pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately two billion people globally. BRIMOCHOL PF has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) and has submitted its NDA to the US FDA. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, AlbionVC, British Business Bank (formerly British Patient Capital), Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and Wille AG. To learn more, visit tenpointtherapeutics.com and connect on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
20 minutes ago
- Business Wire
Circus SE Moves Global Headquarters to Munich
MUNICH--(BUSINESS WIRE)--Circus SE (XETRA: CA1), a global technology company in AI software and autonomous robotics for the food service industry, today announces the relocation of its global headquarters to Munich, marking a strategic move to strengthen its position in one of Europe's most dynamic technology hubs. With a strong foundation already laid in the region through years of mechanical engineering and robotics development, the company is doubling down on Munich as its core location for AI innovation, advanced robotics, and pre-series production of its new CA-M military-grade autonomous robot platform. 'As OpenAI, NVIDIA and other global leaders invest in Munich and the global demand for intelligent automation surges, Munich has become one of the few places in the world where cutting-edge research meets world-class engineering talent,' said Nikolas Bullwinkel, CEO and Founder of Circus. 'We're building the future of robotics here – from our civilian food service automation to next-gen defense solutions – and Munich will be our long-term launchpad.' The new HQ will serve as a central R&D hub, attracting top talent and enabling closer collaboration with leading universities, research centers, and the region's industrial base. 'The ecosystem in Munich is continuously evolving into a global hotspot for robotics and AI,' says Dr. Arne Rost, member of the Circus Advisory Board Member and Managing Director of the Venture Lab Robotics/AI from the Technical University Munich. 'The city brings together academic excellence, entrepreneurial drive, and international deep-tech talent – and Circus is one of the most ambitious companies actively shaping this ecosystem.' Circus' expansion signals a broader trend of global tech players choosing Munich as their base to scale high-impact innovation. With serial production underway and global deployments of its robotics system CA-1 lined up, Circus is set to redefine how intelligent machines integrate into everyday life — and Munich is where that future begins. About Circus SE Circus SE (XETRA: CA1) is a global technology company in the field of embodied AI and AI software for the food service industry, driving innovation and autonomy in labor-intensive sectors. With its core product, the CA-1 robot, Circus is a pioneer in applying embodied AI, integrating cutting-edge technologies into real-world operations, and transforming the food service industry. By combining advanced robotics, AI-driven software, and a mission to solve global challenges, Circus is shaping the future of autonomous systems and redefining human-AI collaboration. Headquartered in Germany and with a rapidly growing international presence, Circus leads the next generation of AI applications.
Business Wire
30 minutes ago
- Business Wire
Dubai Retains Global Top Spot for Attracting Greenfield FDI Projects in Cultural and Creative Industries in 2024
DUBAI, United Arab Emirates--(BUSINESS WIRE)--(Dubai Culture) Dubai has maintained its first place as the world's leading destination for greenfield foreign direct investment (FDI) in the cultural and creative industries (CCI), topping the Financial Times' fDi Markets ranking for the third consecutive year. The 2024 report, which assessed 233 cities under the 'Creative Industries Cluster' classification, placed Dubai ahead of global hubs such as London and Singapore. During the year, the emirate attracted 971 CCI projects—an 8% increase from 2023—bringing in AED 18.86 billion in capital inflows, up nearly 60% from 2023, and generating 23,517 new jobs, a 9% year-on-year rise. All major CCI subsectors saw stronger performance, with notable growth in advertising and PR, film and media production, gaming, education, and advanced software design. According to the Dubai FDI Monitor, greenfield, wholly-owned ventures made up 76.5% of all projects, while new forms of investment represented 15.4%, reinvestment 5.6%, and mergers & acquisitions (2.4%). Data from the Dubai FDI Monitor and the Dubai Framework for Cultural Statistics show that the United States accounted for the largest share of capital inflows in 2024, at 23.2%, followed by India (13.4%), the United Kingdom (9.4%), Switzerland (7.6%), and Saudi Arabia (4.8%). India led in both the number of projects (18.8%) and jobs (18.5%), while the UK, US, Germany, Italy, and France also featured prominently across both metrics. Investor confidence continues to be driven by Dubai's pro-business reforms, including Executive Council Resolution 11 of 2025, which enables free zone businesses to operate onshore, expanding commercial flexibility. The city's Zero Government Bureaucracy programme is also reducing red tape across more than 2,000 federal procedures. Combined with strong intellectual property protections and advanced digital infrastructure, these initiatives have helped establish a regulatory framework marked by efficiency, transparency, and ease of doing business. Insights from the ' Creative Dubai: Navigating Tomorrow's Creative Landscape' report illustrate how this ecosystem is scaling with demand, pinpointing investment opportunity hotspots in design, immersive media and AI-driven production. Dubai continues to offer investors access to top-tier talent, competitive setup costs, and strategic connectivity. The 2024 FDI results underscore the city's rise as a global hub for innovation and one of the world's most attractive environments for creative enterprise.
Business Upturn
an hour ago
- Business Upturn
Alembic Pharma shares dip over 2% after USFDA issues 4 observations for Panelav facility
By Aman Shukla Published on June 2, 2025, 10:25 IST Shares of Alembic Pharmaceuticals fell over 2% on Monday following news that the United States Food and Drug Administration (USFDA) issued four observations after inspecting the company's API-I & II facility at Panelav, Gujarat. As of 10:22 AM, the shares were trading 1.88% lower at Rs 998.90. The unannounced, routine cGMP (current Good Manufacturing Practices) inspection was conducted between May 26 and May 31, 2025. At the conclusion of the inspection, the USFDA issued a Form 483 outlining four observations. Importantly, Alembic confirmed that none of the observations relate to data integrity — a key concern for regulators and investors. The company stated that it will submit a comprehensive response to the USFDA within the required timeframe. Management emphasized that the issues raised are 'addressable' and reiterated its commitment to maintaining high standards of quality and regulatory compliance. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
